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Background and Purpose—Stroke has global importance and it causes an increasing amount of human suffering and
economic burden, but its management is far from optimal. The unsuccessful outcome of several research programs
highlights the need for reliable data on which to plan future clinical trials. The Virtual International Stroke Trials
Archive aims to aid the planning of clinical trials by collating and providing access to a rich resource of patient data
to perform exploratory analyses.
Methods—Data were contributed by the principal investigators of numerous trials from the past 16 years. These data have
been centrally collated and are available for anonymized analysis and hypothesis testing.
Results—Currently, the Virtual International Stroke Trials Archive contains 21 trials. There are data on 15 000 patients
with both ischemic and hemorrhagic stroke. Ages range between 18 and 103 years, with a mean age of 6912 years.
Outcome measures include the Barthel Index, Scandinavian Stroke Scale, National Institutes of Health Stroke Scale,
Orgogozo Scale, and modified Rankin Scale. Medical history and onset-to-treatment time are readily available, and
computed tomography lesion data are available for selected trials.
Conclusions—This resource has the potential to influence clinical trial design and implementation through data analyses
that inform planning. (Stroke. 2007;38:1905-1910.)
Key Words: clinical trials  trial design  natural history  database  modified Rankin Scale
 National Institutes of Health Stroke Scale
Stroke is a major cause of mortality and severe disability indeveloped countries1 and has immense financial and
social implications. Stroke management is estimated to cost
the United States alone between $30 and $40 billion per year.
After the age of 55, the risk of stroke almost doubles with
each successive decade,2 further contributing to the financial
burden of stroke as the population ages.3
The development of drugs for clinical use in acute stroke
has remained slow since the licensing of recombinant tissue-
type plasminogen activator.4 Drugs such as pro-urokinase5
and ancrod,6 which seemed promising, have yet to be ap-
proved for marketing. Similarly, translating the success of
neuroprotective agents in animal models or phase II trials into
efficacy in phase III trials has been troublesome.7 With the
exception of recombinant tissue-type plasminogen activator
and, arguably, recombinant factor VII,8 there has been little
impact on clinical practice. The failure of many trials to
confirm efficacy has generated a need for reliable data on
which to plan future trials.
Many studies worldwide have investigated the risk fac-
tors,9 etiology, geographic occurrence, ethnic disparity,10 and
potential benefits of treatment regimens for stroke. The data
sets from such studies reside in industry and academic
archives long after the studies were published, but the
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importance of the information contained within them is often
underestimated.
By collating these data sets, a large and rich pool of
information can be used for novel analysis of the natural
history of homogeneous subgroups of stroke patients. This
wealth of valuable information could inform the design of
future randomized clinical trials. It could also allow testing of
specific hypotheses. The Virtual International Stroke Trials
Archive (VISTA) was set up in the spirit of contributing to
mutually beneficial ventures to aid progress and break-
throughs in stroke clinical trials.
Methods
Aims of VISTA
VISTA has been established to promote excellence in stroke care and
trial design. It is a collaborative venture involving clinical scientists
from numerous international groups with experience in designing
and conducting clinical trials in acute stroke. The main aim of
VISTA is to facilitate the planning of randomized clinical trials.
Through the collation and categorization of numerous clinical trials,
the VISTA collaboration seeks to bring together under one umbrella
large data sets that would have otherwise ordinarily been left
dormant within university and industry archives. The VISTA data-
base does not sanction reanalysis of any trial data that will test
treatment effects; rather, it provides an unrivalled opportunity to
access a large volume of patient data on which to perform novel
exploratory analyses that would ultimately aid clinical trial design
and development. This represents a major international resource, and
the background and methods of data compilation are detailed here
both to encourage potential collaborators to develop proposals for
future analysis and to facilitate citation of the methodology in their
reports.
Establishment of VISTA
Previous reluctance to amass data in this way was related to issues
such as patient confidentiality, commercial sensitivity, reliability of
data, authorship or intellectual property of a particular study, and its
scientific merit. Similarly, investigators were apprehensive about the
loss of control over the potential use or misuse of such data. These
issues have been addressed through stringent guidelines11 detailing
the handling of confidential patient information, ethics, repre-
sentation, and publication. A Steering Committee comprising prin-
cipal investigators from the contributing trials was established to
judge the scientific merit and approve the proposed uses of trial data.
The criteria used in this process include assessment of originality,
scientific quality, potential for value to the wider scientific commu-
nity, and publication potential. The data also require secure storage
and restriction of access to authorized individuals only. Strict criteria
have been implemented to ensure data protection. These detail the
VISTA constitution, eligibility criteria, promotion, data storage,
compatibility, and documentation.
Policy
VISTA has been designed to improve stroke care and trial design
without favoring a particular organization, sponsor, or individual
group. Membership in VISTA is therefore open to all trials and
registries that meet the eligibility criteria, and the results of analyses
carried out with the use of this resource should be used for the benefit
of the wider population in academia, clinics, and industry. Member-
ship is granted to trials and organizations rather than to individuals,
and each organization should be represented on the Steering Com-
mittee by a named individual, usually the principal investigator.
Selection of Trials
The criteria for trial entry into VISTA are summarized in Table 1.
Setting entry requirements and eligibility criteria for VISTA facili-
tates data compatibility and validity of analyses. However, data sets
that do not completely conform to all of the criteria may still be
considered for entry into VISTA: the intention is to be inclusive.
Data Storage and Documentation
The data are stored at the Robertson Centre for Biostatistics,
University of Glasgow, Glasgow, UK. Trial representatives also
have the option to retain their own converted or annotated data and
merely to provide the data to investigators at the time of agreed
analyses. VISTA holds only anonymized data, as the majority of the
informed consent and institutional review board approvals that have
been gathered restrict storage and transmission to anonymized data.
Within analyses, data are also masked with respect to trial source.
The issue of data compatibility is addressed by the conversion of
all data sets into a standardized form by use of the SAS 9.1 statistical
package (SAS Institute, Inc). SAS 9.1 permits transfer and import of
data in other formats such as Microsoft Excel, Access, SPSS, and
other versions of SAS. The issues of data comparability have also
been addressed through documentation of variables and the inclusion
of data dictionaries alongside trials to explain the type, range, and
units of each variable.
Promotion of VISTA
In its nascent phase, VISTA was promoted through word of mouth;
however, VISTA now accepts the submission of proposals and the
transfer of data electronically. A web portal encourages investigators
to propose projects to be performed with VISTA.12 Anonymized data
are accessible to examine whether the resource has the ability to
accommodate specific end points or variables, and potential inves-
tigators may use the site to select and request specific variables for
their proposed project.
The website also provides a forum through which the Steering
Committee can review proposed projects to assess their viability,
scientific merit, and relevance to VISTA aims. After acceptance of a
written proposal, data are compiled and anonymized and can be sent
through a secure web space to the investigator for local analysis, or
analyses can be carried out centrally under the direction of the
proposing author(s). VISTA actively encourages participation and
inclusion of new collaborators through its website. An efficient
approach for data transfer has the potential to encourage new
partnerships and to reduce time frames of research projects.
Content of VISTA
Description of the contents of VISTA was integral to promotion of
the database as a clinical resource. Data dictionaries are available for
most trials in VISTA, but in some cases, additional information has
been sought to clarify certain variables. Table 2 shows summary
statistics on data held within VISTA as of September 20, 2006.
Recruitment into VISTA is ongoing, and this table displays only
TABLE 1. Eligibility for Entry Into VISTA
Minimum data set of 100 patients
Documented entry criteria
Documented consent or waiver of consent after local institutional review
board–approved procedure
Baseline assessment within 24 hours of stroke onset
Baseline assessment includes recording of neurologic deficit by Oxford,
NIHSS, SSS, or similar
Confirmation of stroke diagnosis by cerebral imaging within 7 days
Outcome assessed between 1 and 6 months after stroke onset
Outcome assessment includes recording of at least 1 of NIHSS, SSS,
Rankin, Barthel Index, or GOS
Monitoring procedures existed to validate data
NIHSS indicates National Institutes of Health Stroke Scale; SSS, Scandina-
vian Stroke Scale; and GOS, Glasgow Outcome Scale.
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those trials containing 100 patients in published or unpublished
studies.
As of September 2006, the VISTA database contains information
from 21 trials that met the VISTA criteria (Table 3), with individual
data on 15 000 patients. Accumulation of these data took several
years and involved collaborations among medical health profession-
als, trial coordinators in industry, and statisticians worldwide.
Twenty trials contain data on patients who experienced an
ischemic stroke; 7 trials also contain data on patients who experi-
enced an intracerebral hemorrhage. Currently, data are held for
13 029 patients with index ischemic stroke and for 1202 patients
with index intracerebral hemorrhage.
VISTA contains data on patients between 18 and 103 years old,
with data on 8129 men and 6897 women (Table 2). Patient data also
include 90-day Scandinavian Stroke Scale; Barthel Index; modified
Rankin Scale; National Institutes of Health Stroke Scale; and
Orgogozo, Mathews, and European Stroke Scales. All 21 trials in the
archive include the Barthel Index as a means of classifying func-
tional ability after stroke; 10 trials include the National Institutes of
Health Stroke Scale; 8 trials include the Scandinavian Stroke Scale;
3 describe the original Rankin Scale; and 12 have used the modified
version. Sixteen of these 21 trials in the archive have a primary end
point at 3 months, and 4 trials continued follow-up to 6 months. One
trial ended at 21 days (Table 4). Measures of the SF-36 Health
Survey, Orgogozo, Glasgow Coma Score, and European Stroke
Scales are also selectively available.
Additional baseline data are available, including computed tomog-
raphy imaging indicating the nature and cause of the stroke,
hemispheric location, any corresponding midline shift, handedness
of the patient, and evolution of the infarct or hemorrhagic transfor-
mation. Medical histories are also available, including such items as
incidence of prior stroke or myocardial infarction, smoking history,
and presence of diabetes and hypertension. The date of stroke onset,
time between ictus and intervention, race, height, weight, and
baseline blood pressure are also available for selected trials. Table 3
describes the treatments used in the trials contained within VISTA.
However, trial treatment data are concealed during analyses to
prevent identification of individual trials or reanalysis of therapeutic
effect. Control group data alone are also available for some studies.
Discussion
There have been limited developments in the transition
between animal studies and clinical application of new
therapies for stroke. More than 4000 published articles have
described the potential efficacy of drugs for stroke therapy.13
However, with the exclusion of a few drugs, none have had a
bearing on clinical practice, and only 2 promising candidates
are waiting in the wings (NXY-05914 and citicoline15). Trial
design has altered little over the years, yet it is clear that we
are not yet routinely applying optimal selection criteria,
end-point choices, or analysis approaches.16,17 VISTA facili-
tates access to a wide range of patient data from randomized
trials and should further promote the effective design of
future clinical trials.
For each case in VISTA, we can examine the relation
between baseline prognostic factors, including concomitant
treatments, and outcome measures. Thus, natural history
analyses can be adjusted for many covariates. Investigators
can specify whether their data set contains placebo and/or
treatment group data, and, if necessary, these data can be used
to conduct sensitivity analyses with output made available to
VISTA investigators only in a form that does not compromise
the anonymity of the trial(s).
TABLE 2. Summary of Demography Statistics
Variable No. of Records Frequency Counts Description (Median IQR*)
Age 15 139    71 62, 78
Sex 15 026 M8129, F6897   
Onset to treatment, h 14 209    5.6 4.0, 9.0
Type of stroke 12 212 Ischemic13 029, intracerebral
al hemorrhage1202
  
Barthel Index at 3 months 6284    85 45, 100
NIHSS at 3 months 2244    4.0 1,10
SSS at 3 months 7701    48 31, 56
mRS at 3 months 5498    2.0 0, 4
Mortality at 3 months 12 729 Dead2739   
IQR indicates interquartile range; NIHSS, National Institutes of Health Stroke Scale; SSS, Scandinavian Stroke Scale;
and mRS, modified Rankin Scale.
TABLE 3. VISTA Trial Contents
Trial Name Intervention
A20 Ancrod
STAT Ancrod
ESTAT33 Ancrod
CMZ000920 Clomethiazole
ECASSI21 Alteplase
ECASSII22 Alteplase
GAIN Americas23 Gavestinel
GAIN International24 Gavestinel
IMAGES25 Magnesium sulfate
INT-1326 Lubeluzole
INT-5 Lubeluzole
INT-9 Lubeluzole
INWEST27 Nimodipine
SELFOTEL_0728 Selfotel
SELFOTEL_1028 Selfotel
ASK29 Streptokinase
TAIST30 Tinzaparin
TRUST31 Nimodipine
STICH32 Surgery for intracerebral hemorrhage
mRECT Repinotan
NINDS4 Tissue-type plasminogen activator
Ali et al Virtual International Stroke Trials Archive 1907
 at UNIV OF NOTTINGHAM on June 5, 2007 stroke.ahajournals.orgDownloaded from 
Data sets that are used in proposed analyses are compiled
on the basis of data availability; data from single or identified
trials are not released without prior consent of the principal
investigators of these trials. Additionally, investigators are
asked to identify named variables that are essential to their
analyses, and subsequent data sets are compiled by a third
party with no vested interest in the proposed study. This
eliminates selection bias. VISTA trials include positive,
neutral, and negative trials, but because the data of interest are
those from placebo-treated patients and because the actively
treated groups would be disregarded in any case where
treatment effect was present, the issue of bias becomes less
relevant.
Steering Committee approval is required before data can be
compiled and released and for subsequent publications. Prin-
cipal investigators whose trials were included in the data set
thus have an opportunity to contribute to authorship decisions
and retain control over dissemination of their data. In partic-
ular, these investigators are able to veto an analysis that
would inadvertently reexamine and reveal treatment effect
within their trial; in practice, such issues would likely be
resolved by discussion and through independence of the
statistical group.
Data from the nascent VISTA were used to develop the
forced allocation system that was used to achieve an average
onset-to-treatment time of 4 hours in the SAINT I trial.14
Currently, VISTA has 14 ongoing projects involving natural
history data that may inform future trials. Questions under
investigation include the incidence of congestive heart failure
after index stroke in placebo-treated patients to provide
guidance on the use of fluids early after stroke. VISTA is also
involved in the early stages of a collaborative clinical trial.
The resource will be used to provide matched historical
comparator data for patients participating in a device trial.
Other areas of investigation include the incidence of serious
adverse events between 1 and 3 months after index stroke,
with an aim to examine the feasibility and validity of using
earlier follow-up periods in trial practice. An examination of
electrocardiographic data from VISTA has also recently been
completed.18
In addition to VISTA, other databases are available to carry
out analyses, such as the German Stroke Databank19 and the
Database of the German Stroke Unit Register Study Group.4
Similarities exist in principle between the German Stroke
Databank and VISTA. The German Stroke Databank is a
multicenter, hospital-based registry of stroke patients who
were registered between 1998 and 1999. It has been used as
a resource for epidemiology, etiology, management, and
outcome in stroke patients. VISTA has similar aims, but it
includes specific subsets of patients who have been enrolled
TABLE 4. Data Availability for the VISTA Archive
Trial No.,
Name Sex Age
Onset to
Treatment, h N
Medical
History
CT
Imaging BI SSS NIHSS mRS Ischemic ICH Follow-Up Other
1, A20 ‡ ‡ 8 0–500 ‡ ‡ ‡ ‡ 6 mo
2, STAT ‡ ‡ 3 0–500 ‡ ‡ ‡ ‡ ‡ 90 d
3, ESTAT ‡ ‡ 10 1501–2000 ‡ ‡ ‡ ‡ ‡ ‡ 3 mo RDRS
4, ECASS I ‡ ‡ 6 501–1000 ‡ ‡ ‡ ‡ ‡ ‡ ‡ 90 d
5, ECASS II ‡ ‡ 6 501–1000 ‡ ‡ ‡ ‡ ‡ ‡ ‡ 90 d SF–36
6, GAINAM ‡ ‡ 6 1501–2000 ‡ ‡ ‡ ‡ ‡ ‡ ‡ 3 mo TOAST
7, GAININT ‡ ‡ 6 1501–2000 ‡ ‡ ‡ ‡ ‡ ‡ ‡ 3 mo TOAST, OCSP
8, SEL07 ‡ ‡ 6 0–500 ‡ ‡ ‡ ‡ ‡ ‡ 90 d
9, SEL10 ‡ ‡ 6 0–500 ‡ ‡ ‡ ‡ ‡ ‡ 90 d
10, CMZ ‡ ‡ 12 501–1000 ‡ ‡ ‡ ‡ ‡ ‡ ‡ 90 d Adams’
Stroke Scale
11, ASK ‡ ‡ 4 0–500 ‡ ‡ ‡ ‡ 3 mo CNS, GCS
12, IMAGES ‡ ‡ 12 2501–3000 ‡ ‡ ‡ ‡ ‡ 90 d RS
13, INWEST ‡ ‡ 24 0–500 ‡ ‡ ‡ ‡ 21 d Orgogozo,
Mathews,
GCS
14, TAIST ‡ ‡ 48 1001–1500 ‡ ‡ ‡ ‡ ‡ ‡ 6 mo SF–36
15, TRUST ‡ ‡ 48 1001–1500 ‡ ‡ ‡ ‡ 6 mo Orgogozo,
Nottingham
Scales
16, INT-5 ‡ ‡ 7 0–500 ‡ ‡ ‡ ‡ ‡ 12 wk ESS, RS
17, INT-9 ‡ ‡ 8 0–500 ‡ ‡ ‡ ‡ ‡ ‡ ‡ 12 wk RS
18, INT-13 ‡ ‡ 8 501–1000 ‡ ‡ ‡ ‡ ‡ ‡ 12 wk ESS
19, STICH ‡ ‡ 72 0–500 ‡ ‡ ‡ ‡ ‡ 6 mo GOS, RS,
GCS
20, MRECT ‡ ‡ 4.5 501–1000 ‡ ‡ ‡ ‡ ‡ ‡ 3 mo SIS–16
21, NINDS ‡ ‡ 3 501–1000 ‡ ‡ ‡ ‡ ‡ ‡ 3 mo GOS, RS
CT indicates computed tomography; BI, Barthel Index; SSS, Scandinavian Stroke Scale; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin
Scale; ICH, intracerebral hemorrhage; RDRS, Rapid Disability Rating Scale; SF-36, Medical Outcomes Study 36-item Short-Form Health Survey; OCSP, Oxfordshire
Community Stroke Project; CNS, Canadian Neurological Scale; GCS, Glasgow Coma Scale; RS, Rankin Scale; ESS, European Stroke Scale; GOS, Glasgow Outcome
Scale; and SIS-16, Stroke Impact Scale-16.
‡denotes the presence of a variable.
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in international clinical trials of various therapies. The inter-
national relevance of the VISTA data, the larger sample, and
the concentration on trial-eligible patients are unique but
complementary features. Certain Cochrane Review groups
also hold individual patient data for meta-analysis purposes:
unlike those groups, VISTA does not plan for or permit
examination of treatment effects, nor are the data restricted to
a single trial topic. Again, the meta-analysis groups provide
complementary opportunities; VISTA is distinct through
encouraging data sharing and having a mechanism for han-
dling external proposals.
Editors of reputable medical journals will no longer accept
manuscripts of trials that have not been registered in an open
database and for which the authors have not had access to the
complete data. Many institutional review boards or national
ethics committees apply similar rules. There can be little
prospect of harm and substantial potential for universal gain
from lodging trial data for at least the control group in a
resource that will be used to improve future research and
clinical care for the participating patient community. Some
national grant-awarding bodies, such as the UK Medical
Research Council, expect completed trial data to be available
to their community. VISTA provides a mechanism for se-
curely lodging, maintaining, and accessing such data for
approved purposes. Perhaps it is time that registration of
stroke trial data within VISTA or a similar resource should
also be mandatory.
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